CTOs on the Move

FerGene

www.fergene.com

 
FerGene is a new gene therapy company dedicated to creating and delivering innovative solutions to urologists and those affected by non-muscle invasive bladder cancer (NMIBC).
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.fergene.com
  • 245 Main Street
    Cambridge, MA USA 02142
  • Phone: 617.865.5780

Executives

Name Title Contact Details

Similar Companies

HotSpot Therapeutics

HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways.

Rapid Pathogen Screening

Founded in 2004, Rapid Pathogen Screening is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.

Stowers Resource Management

Stowers Resource Management is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BIND Therapueitics

BIND Therapueitics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunomic Therapuetics

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing ground-breaking next generation LAMP DNA vaccines, beginning with allergy, cancer and infectious disease.